VASTERA
Bastera is a biotech company with the primary goal of developing groundbreaking treatments for cardiovascular and cancer diseases. Their approach involves targeting new redox signaling pathways, aiming to pioneer "first-in-class" therapies in these fields. Vastera was established in 2018 when SangWon Kang, a professor at Ewha Womans University, transferred a patent based on research results on redox signaling in blood vessels and cancer.
VASTERA
Industry:
Biotechnology Health Care Life Science
Founded:
2018-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.vasthera.com
Total Employee:
11+
Status:
Active
Total Funding:
23.5 B KRW
Technology used in webpage:
Euro SPF Microsoft Exchange Online Office 365 Mail Pound Sterling Microsoft Azure DNS Japanese Yen SK Broadband
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapyโbased treatments for cardiovascular disease.
Investors List
Daesung Private Equity
Daesung Private Equity investment in Series B - Vastera
Medytox Venture Investment
Medytox Venture Investment investment in Series B - Vastera
ID ventures
ID ventures investment in Series B - Vastera
SJ Investment Partners
SJ Investment Partners investment in Series B - Vastera
Partners Investment
Partners Investment investment in Series B - Vastera
Shinhan Venture Investment
Shinhan Venture Investment investment in Series B - Vastera
Medici Investment
Medici Investment investment in Series B - Vastera
UTC Investment Co.
UTC Investment Co. investment in Series B - Vastera
Premier Partners
Premier Partners investment in Venture Round - Vastera
Official Site Inspections
http://www.vasthera.com
- Host name: swpni.co.kr
- IP address: 58.229.176.26
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Vastera"
VasThera
VasTheraSee details»
Vastera - Crunchbase Company Profile & Funding
Organization. Vastera . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Legal Name VasThera Co., Ltd. Company Type For โฆSee details»
VasThera Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore VasThera Co., Ltd. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Neoplasms, Nervous System Diseases, Technology Platform ...See details»
VasThera
2018 ~ present CEO and Founder, VasThera Co., Ltd. 2002 ~ present Professor, Department of Life Science, Ewha Womans University, Korea; 2002 ~ 2007 CSO, Life Science Institute, โฆSee details»
VasThera Company Profile 2024: Valuation, Funding & Investors
VasThera General Information Description. Operator of a pharmaceutical company dedicated to developing synthetic therapeutics targeting vascular hyperplasia. The company develops โฆSee details»
VasThera Co., Ltd. (VasThera Co., Ltd.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
ไบ่งฃVasThera Co., Ltd. (VasThera Co., Ltd.)ๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็๏ผ็พ็ ้ขๅ:็ฅ็ป็ณป็ป็พ็ ๏ผ่ฟ็ค๏ผๆๆฏๅนณๅฐ:ๅฐๅๅญๅ่ฏ๏ผ้ ถ๏ผๅๅญฆ่ฏ๏ผ็็ฉ่ฏ๏ผ่ฏ็ฉ:VTA โฆSee details»
VASTHERA Company Profile - Office Locations, Competitors ... - Craft
VASTHERA is a pharmaceutical company that develops synthetic therapeutics targeting vascular hyperplasia. It provides drug candidates for pulmonary arterial hypertension treatment. The โฆSee details»
VasThera
News VasThera won the Prize of Minister (Ministry of SMEs and Startups) VasThera([email protected]) Date : 2023-01-03 View : 3346 . ... Dr. Sang Won Kang โฆSee details»
Vasthera - Products, Competitors, Financials, Employees, โฆ
Vasthera is an innovative pharmaceutical company focused on developing synthetic therapeutics for vascular diseases. The company specializes in creating first-in-class vascular therapeutics โฆSee details»
VASTHERA - VentureRadar
"Vasthera is a pharmaceutical company that develops the first-in-class synthetic therapeutics targeting the vascular hyperplasia. We are: Developing the drug candidates for pulmonary โฆSee details»
VT-N - Drug Targets, Indications, Patents - Synapse - Patsnap
VT-N, Initially developed by VasThera Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous System Diseases, Active Indication ...See details»
๋ฐ์คํ ๋ผ(๋๋งฅํ๊ด ์น๋ฃ์ ) - ๊ธฐ์ ์ ๋ณด | ํฌ์, ๋งค์ถ, ๊ธฐ์ ๊ฐ์น - THE VC
์ฃผ์ํ์ฌ ๋ฐ์คํ ๋ผ(VasThera)๋ 2018๋ 1์์ ์ค๋ฆฝ๋ ํ๊ตญ๊ณโ์ค์๊ธฐ์ ์ ๋๋ค. ๋ฐ์ด์ค/์๋ฃโ๋ด๊ณผ ๋ถ์ผ์ ๋๋งฅํ๊ด ์น๋ฃ์ ๊ฐ ์ฃผ์ ์ ํ/์๋น์ค์ ๋๋ค. ๋ณธ์ฌ๋ ํ๊ตญโ์์ธํน๋ณ์์ ์์นํด์์ต๋๋ค. โฆSee details»
VasThera
VasThera([email protected]) Date : 2022-06-14 View : 4204 . ... The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the worldโs largest โฆSee details»
VTA-04 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 VTA-04, Initially developed by VasThera Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Respiratory Diseases,Other Diseases, Active ...See details»
VasThera
Dr. Sang Won Kang attended a business exchange meeting at the Korea Biotech Industry Organization View more. News 2022-09-27 VasThera signs MoU with IBS for Study on the โฆSee details»
QUALTHERA
At Qualthera, we are dedicated to providing innovative, custom medication solutions for both healthcare providers and patients. Our mission is to deliver quality therapy for life, ensuring โฆSee details»
VTC-04 - Drug Targets, Indications, Patents - Synapse - Patsnap
VTC-04, Initially developed by VasThera Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms,Skin and Musculoskeletal Diseases ...See details»
VaxThera, a SURA Company Created in Colombia for the
Jun 29, 2021 This post is also available in: Español (Spanish) Created with a projected investment of 54 million dollars made by Seguros SURA Colombia in its first stage, and the โฆSee details»
VTA-05 - Drug Targets, Indications, Patents - Synapse
VTA-05, Initially developed by VasThera Co., Ltd., Now, its global highest R&D status is Discontinued, Therapeutic Areas: Cardiovascular Diseases.See details»
VTA-10 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 OBJECTIVES To assess the clinical and radiographic outcomes of the regenerative treatment of peri-implantitis using a vancomycin and tobramycin impregnated โฆSee details»